Rapid advancements have been made in drug therapy for heart failure in recent years, and guideline-directed medical therapy (GDMT)-including β-blockers, mineralocorticoid receptor antagonists (MRA), sodium glucose cotransporter-2 (SGLT2) inhibitors, and angiotensin receptor blockers/angiotensin converting enzyme inhibitors/angiotensin receptor neprilysin inhibitor (ARNI), is strongly recommended. The gene discussed is SLC5A2; the disease is heart failure.